Advances in pharmacotherapy for the treatment of allergic rhinitis

MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps

Jean Bousquet, Claus Bachert, Jonathan Bernstein, G Walter Canonica, Warner Carr, Ronald Dahl, Pascal Demoly, Philippe Devillier, Peter Hellings, Wytske Fokkens, Ludger Klimek, Phil Lieberman, Eli Meltzer, David Price, Dermot Ryan, Ulrich Wahn

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

INTRODUCTION: Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.

AREAS COVERED: This article reviews the clinical data for a new AR treatment. MP29-02 (Dymista®, Meda, Solna, Sweden) contains azelastine hydrochloride (AZE) and fluticasone propionate (FP), in a novel formulation and delivered in an improved device as a single nasal spray. It has shown superior efficacy in AR patients than either commercially available AZE or FP monotherapy for both nasal and ocular symptom relief, regardless of disease severity. MP29-02 also provided more effective and rapid symptom relief than either AZE or FP monotherapy delivered in the MP29-02 formulation and device. However, the effect was less than that observed versus commercial comparators, suggesting the impact of formulation and device on clinical efficacy.

EXPERT OPINION: MP29-02 simplifies AR management, surpassing the efficacy of gold standard treatment, intranasal corticosteroids (INS), for the first time. It is indicated for the treatment of moderate-to-severe seasonal allergic rhinitis and perennial allergic rhinitis when monotherapy with either intranasal antihistamine or INS is NOT considered sufficient. Most patients present with moderate/severe disease, with evidence of current or previous treatment insufficiency. MP29-02 should be the treatment of choice for these patients.

Original languageEnglish
Pages (from-to)913-928
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number6
Early online date7 Mar 2015
DOIs
Publication statusPublished - 2015

Fingerprint

azelastine
Drug Therapy
Therapeutics
Equipment and Supplies
Adrenal Cortex Hormones
Rhinitis, Allergic, Perennial
Nasal Sprays
Fluticasone
MP29-02
Allergic Rhinitis
Seasonal Allergic Rhinitis
Histamine Antagonists
Nose
Sweden

Keywords

  • allergic rhinitis
  • ARIA
  • azelastine
  • fluticasone
  • MP29-02
  • treatment

Cite this

Advances in pharmacotherapy for the treatment of allergic rhinitis : MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. / Bousquet, Jean; Bachert, Claus; Bernstein, Jonathan; Canonica, G Walter; Carr, Warner; Dahl, Ronald; Demoly, Pascal; Devillier, Philippe; Hellings, Peter; Fokkens, Wytske; Klimek, Ludger; Lieberman, Phil; Meltzer, Eli; Price, David; Ryan, Dermot; Wahn, Ulrich.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 6, 2015, p. 913-928.

Research output: Contribution to journalArticle

Bousquet, J, Bachert, C, Bernstein, J, Canonica, GW, Carr, W, Dahl, R, Demoly, P, Devillier, P, Hellings, P, Fokkens, W, Klimek, L, Lieberman, P, Meltzer, E, Price, D, Ryan, D & Wahn, U 2015, 'Advances in pharmacotherapy for the treatment of allergic rhinitis: MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps', Expert Opinion on Pharmacotherapy, vol. 16, no. 6, pp. 913-928. https://doi.org/10.1517/14656566.2015.1020789
Bousquet, Jean ; Bachert, Claus ; Bernstein, Jonathan ; Canonica, G Walter ; Carr, Warner ; Dahl, Ronald ; Demoly, Pascal ; Devillier, Philippe ; Hellings, Peter ; Fokkens, Wytske ; Klimek, Ludger ; Lieberman, Phil ; Meltzer, Eli ; Price, David ; Ryan, Dermot ; Wahn, Ulrich. / Advances in pharmacotherapy for the treatment of allergic rhinitis : MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 6. pp. 913-928.
@article{b981c3d6ded2413bac3e1d84f15616d2,
title = "Advances in pharmacotherapy for the treatment of allergic rhinitis: MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps",
abstract = "INTRODUCTION: Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.AREAS COVERED: This article reviews the clinical data for a new AR treatment. MP29-02 (Dymista{\circledR}, Meda, Solna, Sweden) contains azelastine hydrochloride (AZE) and fluticasone propionate (FP), in a novel formulation and delivered in an improved device as a single nasal spray. It has shown superior efficacy in AR patients than either commercially available AZE or FP monotherapy for both nasal and ocular symptom relief, regardless of disease severity. MP29-02 also provided more effective and rapid symptom relief than either AZE or FP monotherapy delivered in the MP29-02 formulation and device. However, the effect was less than that observed versus commercial comparators, suggesting the impact of formulation and device on clinical efficacy.EXPERT OPINION: MP29-02 simplifies AR management, surpassing the efficacy of gold standard treatment, intranasal corticosteroids (INS), for the first time. It is indicated for the treatment of moderate-to-severe seasonal allergic rhinitis and perennial allergic rhinitis when monotherapy with either intranasal antihistamine or INS is NOT considered sufficient. Most patients present with moderate/severe disease, with evidence of current or previous treatment insufficiency. MP29-02 should be the treatment of choice for these patients.",
keywords = "allergic rhinitis , ARIA, azelastine, fluticasone, MP29-02, treatment",
author = "Jean Bousquet and Claus Bachert and Jonathan Bernstein and Canonica, {G Walter} and Warner Carr and Ronald Dahl and Pascal Demoly and Philippe Devillier and Peter Hellings and Wytske Fokkens and Ludger Klimek and Phil Lieberman and Eli Meltzer and David Price and Dermot Ryan and Ulrich Wahn",
note = "Acknowledgement We thank R Murray from MedScript Ltd Dundalk Ireland for assistance in editing this manuscript.",
year = "2015",
doi = "10.1517/14656566.2015.1020789",
language = "English",
volume = "16",
pages = "913--928",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Advances in pharmacotherapy for the treatment of allergic rhinitis

T2 - MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps

AU - Bousquet, Jean

AU - Bachert, Claus

AU - Bernstein, Jonathan

AU - Canonica, G Walter

AU - Carr, Warner

AU - Dahl, Ronald

AU - Demoly, Pascal

AU - Devillier, Philippe

AU - Hellings, Peter

AU - Fokkens, Wytske

AU - Klimek, Ludger

AU - Lieberman, Phil

AU - Meltzer, Eli

AU - Price, David

AU - Ryan, Dermot

AU - Wahn, Ulrich

N1 - Acknowledgement We thank R Murray from MedScript Ltd Dundalk Ireland for assistance in editing this manuscript.

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.AREAS COVERED: This article reviews the clinical data for a new AR treatment. MP29-02 (Dymista®, Meda, Solna, Sweden) contains azelastine hydrochloride (AZE) and fluticasone propionate (FP), in a novel formulation and delivered in an improved device as a single nasal spray. It has shown superior efficacy in AR patients than either commercially available AZE or FP monotherapy for both nasal and ocular symptom relief, regardless of disease severity. MP29-02 also provided more effective and rapid symptom relief than either AZE or FP monotherapy delivered in the MP29-02 formulation and device. However, the effect was less than that observed versus commercial comparators, suggesting the impact of formulation and device on clinical efficacy.EXPERT OPINION: MP29-02 simplifies AR management, surpassing the efficacy of gold standard treatment, intranasal corticosteroids (INS), for the first time. It is indicated for the treatment of moderate-to-severe seasonal allergic rhinitis and perennial allergic rhinitis when monotherapy with either intranasal antihistamine or INS is NOT considered sufficient. Most patients present with moderate/severe disease, with evidence of current or previous treatment insufficiency. MP29-02 should be the treatment of choice for these patients.

AB - INTRODUCTION: Effective pharmacologic treatment exists for most patients suffering from allergic rhinitis (AR). However, both in clinical trials and in real-life studies, many patients are dissatisfied with treatment. Physicians often use multiple therapies, in an attempt to improve symptom control, often with limited evidence of success. Novel treatment options are needed and must consider unmet medical needs.AREAS COVERED: This article reviews the clinical data for a new AR treatment. MP29-02 (Dymista®, Meda, Solna, Sweden) contains azelastine hydrochloride (AZE) and fluticasone propionate (FP), in a novel formulation and delivered in an improved device as a single nasal spray. It has shown superior efficacy in AR patients than either commercially available AZE or FP monotherapy for both nasal and ocular symptom relief, regardless of disease severity. MP29-02 also provided more effective and rapid symptom relief than either AZE or FP monotherapy delivered in the MP29-02 formulation and device. However, the effect was less than that observed versus commercial comparators, suggesting the impact of formulation and device on clinical efficacy.EXPERT OPINION: MP29-02 simplifies AR management, surpassing the efficacy of gold standard treatment, intranasal corticosteroids (INS), for the first time. It is indicated for the treatment of moderate-to-severe seasonal allergic rhinitis and perennial allergic rhinitis when monotherapy with either intranasal antihistamine or INS is NOT considered sufficient. Most patients present with moderate/severe disease, with evidence of current or previous treatment insufficiency. MP29-02 should be the treatment of choice for these patients.

KW - allergic rhinitis

KW - ARIA

KW - azelastine

KW - fluticasone

KW - MP29-02

KW - treatment

U2 - 10.1517/14656566.2015.1020789

DO - 10.1517/14656566.2015.1020789

M3 - Article

VL - 16

SP - 913

EP - 928

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -